BTAI
Price:
$0.5375
Market Cap:
$21.90M
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials e...[Read more]
Industry
Biotechnology
IPO Date
2018-03-08
Stock Exchange
NASDAQ
Ticker
BTAI
According to BioXcel Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 69.25M. This represents a change of -33.48% compared to the average of 104.11M of the last 4 quarters.
The mean historical Enterprise Value of BioXcel Therapeutics, Inc. over the last ten years is 253.23M. The current 69.25M Enterprise Value has changed 2.63% with respect to the historical average. Over the past ten years (40 quarters), BTAI's Enterprise Value was at its highest in in the June 2020 quarter at 1.01B. The Enterprise Value was at its lowest in in the June 2017 quarter at 0.
Average
253.23M
Median
172.57M
Minimum
0
Maximum
790.27M
Discovering the peaks and valleys of BioXcel Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual Enterprise Value = 790.27M
Minimum Annual Increase = -91.81%
Minimum Annual Enterprise Value = 0
Year | Enterprise Value | Change |
---|---|---|
2023 | 122.09M | -75.69% |
2022 | 502.19M | 64.87% |
2021 | 304.59M | -61.46% |
2020 | 790.27M | 282.53% |
2019 | 206.59M | 1.41% |
2018 | 13.68M | -91.81% |
2017 | 167.04M | -3.20% |
2016 | 172.57M | Infinity% |
The current Enterprise Value of BioXcel Therapeutics, Inc. (BTAI) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
309.63M
5-year avg
385.15M
10-year avg
253.23M
BioXcel Therapeutics, Inc.’s Enterprise Value is less than Terns Pharmaceuticals, Inc. (544.98M), less than Amylyx Pharmaceuticals, Inc. (171.20M), less than Acumen Pharmaceuticals, Inc. (98.44M), less than Inozyme Pharma, Inc. (345.78M), greater than X4 Pharmaceuticals, Inc. (15.46M), less than Day One Biopharmaceuticals, Inc. (981.32M), less than Mirati Therapeutics, Inc. (3.91B), less than Apellis Pharmaceuticals, Inc. (3.37B), less than Exelixis, Inc. (7.51B), less than TG Therapeutics, Inc. (3.42B), less than Viking Therapeutics, Inc. (7.14B), less than Madrigal Pharmaceuticals, Inc. (4.30B), greater than eFFECTOR Therapeutics, Inc. (3.77M), greater than Elevation Oncology, Inc. (1.81M), less than Mereo BioPharma Group plc (567.62M), greater than Hepion Pharmaceuticals, Inc. (1.44M),
Company | Enterprise Value | Market cap |
---|---|---|
544.98M | $636.23M | |
171.20M | $243.05M | |
98.44M | $138.18M | |
345.78M | $314.30M | |
15.46M | $84.45M | |
981.32M | $1.22B | |
3.91B | $4.12B | |
3.37B | $3.26B | |
7.51B | $7.47B | |
3.42B | $3.39B | |
7.14B | $7.18B | |
4.30B | $4.68B | |
3.77M | $131.72K | |
1.81M | $30.34M | |
567.62M | $648.89M | |
1.44M | $3.40M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioXcel Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BioXcel Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is BioXcel Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?
What is the 3-year average Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?
What is the 5-year average Enterprise Value for BioXcel Therapeutics, Inc. (BTAI)?
How does the current Enterprise Value for BioXcel Therapeutics, Inc. (BTAI) compare to its historical average?